Navigation Links
Novagali Pharma Completes a EUR15 Million Fund Raising
Date:9/26/2008

EVRY, France, September 26 /PRNewswire/ -- Novagali Pharma, a French Laboratory specialized in ophthalmology announces today it has secured EUR15 million in a new financing round with the participation of the historical Company investors.

Thanks to this new contribution Novagali Pharma will continue to develop its high potential projects:

- The commercialization in France and abroad of its first

marketable product, Cationorm(R), indicated for the treatment of dry eye

symptoms,

- The development of its flagship products: Vekacia(R) (Vernal

keratoconjunctivitis), Cyclokat(R) (Dry eye), Nova21027 (Glaucoma) and

Cortiject(R) (Diabetic macular edema), and particularly for Cyclokat(R)

the phase III clinical study now in course in Europe and the one

initiated in the United States during the third quarter of 2008 as well

as the phase I finalization in patient with Cortiject(R) started in

April 2008 in the United States.

Jerome Martinez, Novagali Pharma Chief Executive Officer, says: "The total amount of this fund rising strengthens once again our investors confidence to our development strategy, our products and our technological approach. This new source of financing will help us to carry on our company development".

About Novagali Pharma : http://www.novagali.com

Novagali Pharma is an ophthalmic pharmaceutical company that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 7 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis, Cyclokat(R), a product for the treatment of moderate-to-severe dry eye syndrome and Cortiject(R) for the treatment of diabetic retinopathies. Cationorm(R), indicated for dry eye symptoms is commercialized in France since April 2008. Founded in 2000, Novagali Pharma is based in the Genopole biocluster in Evry (France).


'/>"/>
SOURCE Novagali Pharma SA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novagali Pharma Announces the Launch of Cationorm(R)
2. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
3. Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)
4. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
5. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
6. New USP 797 Regulations May Create New Hazards for Compounding Pharmacy Directors
7. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
8. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
9. AIT Laboratories Expands Pharma Services
10. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
11. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is excited to announce the formation of ... developing preclinical ophthalmology assets through proof of concept. ... created by Portage Pharmaceuticals Limited and being developed ... surface and anterior segment diseases. This agent has ...
(Date:11/30/2016)... 30, 2016  Tempus, a technology company focused ... Penn,s Abramson Cancer Center have partnered to better ... to immunotherapy treatment based on next generation genomic ... of a research collaboration, Tempus will provide sequencing ... patient data to Penn. Utilizing next-generation sequencing, machine ...
(Date:11/30/2016)...   Merck , a leading science and technology ... set of agreements with Evotec AG, whereby Evotec AG ... reagents such as CRISPR and shRNA libraries. Combining access ... accelerated pathway to explore and identify new drug targets. ... new targets, a process that can be time- and ...
(Date:11/30/2016)... Triangle Park, North Carolina (PRWEB) , ... November 30, 2016 , ... ... (IUPAC) approved the names and symbols for four elements: nihonium (Nh), moscovium (Mc), ... Following a 5-month period of public review, the names earlier proposed by the discoverers ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
Breaking Biology News(10 mins):